IOncology

The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier interviewed several prominent members of the advisory board who participated in the voting, including Prof. Yiding Chen, Prof. Hengyu Li, Prof. Man Li, Prof. Shu Liu, Prof. Yongsheng Wang, and Prof. Jian Zhang, to provide insights into the potential updates in the 2025 edition.

Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital to launch the Zhōng & Huì Insights clinical progress series. Through in-depth analyses of high-quality clinical research in lung cancer, the series aims to elevate clinical practice standards. In this 24th installment, the professors discuss the results of the study titled "Efficacy and Safety of Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients," published in The Lancet Respiratory Medicine by Dr. Baohui Han as the first author.

At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the Infectious Tumors Subcommittee session, Dr. Qingbo Wang from The Second Hospital of Nanjing presented a report titled "Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer." The presentation explored the epidemiology, diagnostic challenges, and treatment strategies for patients with coexisting tuberculosis (TB) and lung cancer.

The historic city of Xi’an became a gathering place for top global oncologists as the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Socitey (AOS) took place from November 14 to 17. This event symbolized a significant integration of the global oncology community. During the gynecologic oncology session at CCHIO, Dr. Xiaohua Wu from Fudan University Shanghai Cancer Center delivered a presentation titled "Enhancing Preoperative Evaluation Strategies for Advanced Ovarian Cancer Patients." In an exclusive interview with Oncology Frontier, he shared Fudan's experience in advancing preoperative evaluation methods for ovarian cancer.

The era of targeted immunotherapy has revolutionized liver cancer treatment, offering unprecedented therapeutic efficacy. Comprehensive approaches are emerging to enhance patient outcomes, prompting a reevaluation of traditional surgical concepts for liver cancer.

With advancements in local treatment techniques and the emergence of new therapeutic agents, combined local and systemic therapies have demonstrated synergistic effects greater than the sum of their parts in liver cancer management. For patients with intermediate and advanced liver cancer, this approach has improved conversion therapy success rates and even achieved curative outcomes. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the "Interventional Oncology" session, Dr. Ming Zhao from the Sun Yat-sen University Cancer Center shared his insights on the combined treatment approach. Oncology Frontier interviewed Professor Zhao to discuss the theoretical foundations, current developments, and future directions of combined local and systemic therapies.

In the historic city of Xi'an, renowned for its cultural significance, the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Society (AOS) took place from November 14 to 17, creating a global platform for the oncology community. During the CCHIO’s gynecological oncology session, Dr. Jianqing Zhu from Zhejiang Cancer Hospital presented her report on "Precision Diagnosis and Treatment of Platinum-Resistant Recurrent Ovarian Cancer."